Equities Analysts Issue Forecasts for MNMD Q1 Earnings

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD - Free Report) - Research analysts at Leerink Partnrs issued their Q1 2025 earnings estimates for shares of Mind Medicine (MindMed) in a research note issued to investors on Wednesday, January 29th. Leerink Partnrs analyst M. Goodman expects that the company will earn ($0.35) per share for the quarter. Leerink Partnrs has a "Strong-Buy" rating on the stock. The consensus estimate for Mind Medicine (MindMed)'s current full-year earnings is ($1.35) per share.

A number of other equities analysts also recently commented on MNMD. Chardan Capital started coverage on shares of Mind Medicine (MindMed) in a research report on Friday, December 20th. They set a "buy" rating and a $20.00 price objective for the company. Oppenheimer restated an "outperform" rating and issued a $20.00 price objective on shares of Mind Medicine (MindMed) in a research report on Tuesday, December 17th. HC Wainwright reiterated a "buy" rating and set a $55.00 target price on shares of Mind Medicine (MindMed) in a research report on Monday, November 11th. Evercore ISI began coverage on shares of Mind Medicine (MindMed) in a research note on Tuesday. They issued an "outperform" rating and a $23.00 price objective for the company. Finally, Leerink Partners began coverage on shares of Mind Medicine (MindMed) in a research report on Monday, October 14th. They set an "outperform" rating and a $20.00 target price on the stock. Ten investment analysts have rated the stock with a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, Mind Medicine (MindMed) has a consensus rating of "Buy" and an average price target of $26.33.

Mind Medicine (MindMed) Stock Performance

Shares of NASDAQ MNMD traded down $0.19 during mid-day trading on Thursday, hitting $7.13. 1,113,361 shares of the company were exchanged, compared to its average volume of 1,438,655. The stock has a 50 day simple moving average of $7.27 and a 200-day simple moving average of $6.94. Mind Medicine has a 1-year low of $3.82 and a 1-year high of $12.22. The company has a quick ratio of 9.00, a current ratio of 9.00 and a debt-to-equity ratio of 0.09. The firm has a market cap of $522.84 million, a price-to-earnings ratio of -3.15 and a beta of 2.60.

Mind Medicine (MindMed) (NASDAQ:MNMD - Get Free Report) last announced its earnings results on Thursday, November 7th. The company reported ($0.27) earnings per share for the quarter, topping the consensus estimate of ($0.29) by $0.02. During the same quarter last year, the company posted ($0.53) EPS.

Institutional Investors Weigh In On Mind Medicine (MindMed)

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Wealth Enhancement Advisory Services LLC purchased a new stake in Mind Medicine (MindMed) during the 3rd quarter worth $58,000. Sanctuary Advisors LLC purchased a new stake in shares of Mind Medicine (MindMed) in the third quarter worth about $91,000. Foundations Investment Advisors LLC acquired a new stake in shares of Mind Medicine (MindMed) in the fourth quarter valued at about $91,000. Stoneridge Investment Partners LLC acquired a new stake in shares of Mind Medicine (MindMed) in the third quarter valued at about $93,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Mind Medicine (MindMed) during the 3rd quarter valued at about $93,000. 27.91% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Mind Medicine (MindMed)

In related news, insider Dan Karlin sold 6,643 shares of the company's stock in a transaction that occurred on Thursday, December 26th. The shares were sold at an average price of $7.43, for a total transaction of $49,357.49. Following the completion of the transaction, the insider now owns 338,013 shares of the company's stock, valued at approximately $2,511,436.59. This represents a 1.93 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Robert Barrow sold 19,106 shares of Mind Medicine (MindMed) stock in a transaction on Thursday, December 26th. The shares were sold at an average price of $7.43, for a total transaction of $141,957.58. Following the completion of the transaction, the chief executive officer now owns 526,666 shares in the company, valued at approximately $3,913,128.38. This trade represents a 3.50 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 28,022 shares of company stock worth $208,203 over the last ninety days. 2.26% of the stock is currently owned by corporate insiders.

Mind Medicine (MindMed) Company Profile

Mind Medicine (MindMed) Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder.